• Skip to content
  • Skip to navigation

P&A Grant Thornton uses cookies to monitor the performance of this website and improve user experience

To find out more about cookies, what they are and how we use them, please see our privacy notice, which also provides information on how to delete cookies from your hard drive.

Global site
  • Global site
  • Algeria
  • Botswana
  • Cameroon
  • Egypt
  • Ethiopia
  • Gabon
  • Guinea
  • Kenya
  • Libya
  • Malawi
  • Mauritius
  • Morocco
  • Nigeria
  • Namibia
  • Senegal
  • South Africa
  • Togo
  • Tunisia
  • Uganda
  • Zambia
  • Zimbabwe
  • Anguilla
  • Antigua
  • Argentina
  • Aruba, Bonaire, Curacao and St. Maarten
  • Bahamas
  • Barbados
  • Bolivia
  • Brazil
  • British Virgin Islands
  • Canada LLP
  • Canada RCGT
  • Cayman Islands
  • Chile
  • Colombia
  • Costa Rica
  • Dominica
  • Ecuador
  • El Salvador
  • Grenada
  • Guatemala
  • Honduras
  • Mexico
  • Montserrat
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • Puerto Rico
  • St Kitts
  • St Lucia
  • St Vincent and the Grenadines
  • Trinidad & Tobago
  • United States
  • Uruguay
  • Venezuela
  • Turks & Caicos
  • Afghanistan
  • Australia
  • Bangladesh
  • Cambodia
  • China
  • Hong Kong
  • India
  • Indonesia
  • Japan
  • Korea
  • Malaysia
  • Mongolia
  • Myanmar
  • New Zealand
  • Pakistan
  • Philippines
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam
  • Albania
  • Armenia
  • Austria
  • Azerbaijan
  • Belarus
  • Belgium
  • Bosnia and Herzegovina
  • Bulgaria
  • Channel Islands
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Georgia
  • Germany
  • Gibraltar
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Isle of Man
  • Israel
  • Italy - Bernoni
  • Italy - Ria
  • Kazakhstan
  • Kosovo
  • Kyrgyzstan
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malta
  • Moldova
  • Monaco
  • Netherlands
  • Northern Ireland
  • Norway
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Tajikistan
  • Turkey
  • Ukraine
  • UK
  • Uzbekistan
  • Bahrain
  • Egypt
  • Jordan
  • Kuwait
  • Oman
  • Qatar
  • Saudi Arabia
  • United Arab Emirates
  • Yemen
  • Lebanon
Grant Thorton Logo

Grant Thornton Logo Grant Thornton Logo

Contact us
  • Insights
  • Services
  • Industries
  • Meet our people
  • Careers
  • Alerts and Publications
  • Events
  • Locations
  • P&A Foundation, Inc.
  • Audit and Assurance
  • Tax Advisory and Compliance
  • Advisory Services
  • Outsourcing and Managed Services
  • Japan Desk
Audit and Assurance Home
  • Audit approach overview
  • Annual and short period audit
  • Review engagement
  • Other Related Services
Tax Advisory and Compliance Home
  • Tax advisory
  • Tax compliance
  • Corporate services
  • Tax education and advocacy
Advisory Services Home
  • Business risk services
  • Business consulting services
  • Transaction services
  • Forensic advisory
  • Cyber advisory
Outsourcing and Managed Services Home
  • Accounting services
  • Staff augmentation services
  • Payroll Processing
  • Education
  • Consumer products
  • Energy and natural resources
  • Financial services
  • Not for profit
  • Outsourcing
  • Public sector
  • Real estate and construction
  • Technology, media and communications
  • Travel, tourism and leisure
  • Retail industry
  • About
  • P&AUSE
  • P&AUSE Officers
  • Board of Trustees
  • Contact Us
  • Grant Thornton Philippines
  • Alerts and Publications
  • Technical Alerts
  • Tax Alerts
  • 2020
  • VAT-exempt sales/ importations of drugs and medicines prescribed for certain diseases

Tax Alert

10 Jul 2020
  • Tax Alerts
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012

VAT-exempt sales/ importations of drugs and medicines prescribed for certain diseases

(Revenue Regulations No. 18-2020 issued on June 26, 2020)

This Tax Alert is issued to inform all concerned on the implementing rules and regulations on the VAT-exemption of sale or importation of drugs and medicines pursuant to RA 11467.

Sale or importation by the manufacturers, distributors, wholesalers and retailers of prescription drugs and medicines included on the list of approved drugs and medicines by the Department of Health (DOH) for diabetes, high cholesterol, and hypertension shall be VAT-exempt beginning January 27, 2020.

VAT paid on importations of qualified prescription drugs and medicines for diabetes, high cholesterol, and hypertension from effectivity of RA No. 11467 on January 27, 2020 until effectivity of these Regulations (July 09, 2020) may be applied for refund, provided that the VAT was not yet claimed as input tax credit in the VAT returns. Existing procedures for VAT refund shall be followed.

The list of VAT exempt drugs and medicines for diabetes, high-cholesterol and hypertension as published by DOH can be accessed in the below link:

https://www.bir.gov.ph/images/bir_files/internal_communications_2/RMCs/2020%20RMCs/RMC%20No.%2062-2020%20FDA%20List.pdf

Moreover, effective January 01, 2023, sale and importation of prescription drugs for cancer, mental illness, tuberculosis and kidney diseases shall also be VAT-exempt.

.

RR No. 18-2020
Download PDF [159 kb]
rich text with download pdf
Download PDF [159 kb]
Download PDF [159 kb]
  • Follow us on YouTube
  • Follow us on Facebook
  • Follow us on Twitter
  • Follow us on Instagram
CONNECTclose
  • Meet Our People
  • Contact us
  • Our heritage
ABOUTclose
  • About us
  • Careers
  • News Centre
LEGALclose
  • Privacy
  • Cookie policy
  • Disclaimer
  • Site map

© 2021 Punongbayan & Araullo - All rights reserved. “Grant Thornton” refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Punongbayan & Araullo (P&A) is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another’s acts or omissions.

    • EN
    • Contact us